The new versus the old: local anaesthesia techniques examined

Article

A survey of British Ophthalmologists has found that there is a lower rate of serious complications after cataract surgery if sub–Tenon's, topical and topical–intracameral local anaesthesias are used rather than the "older" retrobulbar and peribulbar techniques.

A survey of British Ophthalmologists has found that there is a lower rate of serious complications after cataract surgery if sub–Tenon's, topical and topical–intracameral local anaesthesias are used rather than the 'older' retrobulbar and peribulbar techniques.

Tom Eke of the Norfolk & Norwich University Hospital and John Thompson from the University of Leicester, UK, conducted a prospective, observational study of routine practice in the UK for 13 months during the 2002 - 2003 period. The study was done through the British Ophthalmic Surveillance Unit (BOSU). Each month BOSU contacted all senior UK ophthalmologists asking for recent cases of 'potentially sight–threatening or life threatening complications of local anaesthesia for cataract surgery'.

The results showed that cataract surgery, conducted within the National Health Service (NHS), comprised 4.1% under general anaesthesia, 92.1% with local anaesthesia without sedation and 2.9% with local anaesthesia and sedation. Approximately 375,000 local anaesthesias were given for cataract surgery during the survey period. Of these, 30.6% used the peribulbar technique, 3.5% retrobulbar, 42.6% sub–Tenon's, 1.7% sub–conjunctival, 9.9% topical and 11% topical–intracameral local anaesthesia.

The largest number of potentially sight–threatening complications were reported in association with the retrobulbar and peribulbar technique. Twenty–six cases of globe penetration or perforation, 16 of which resulted in a poor visual outcome, were reported. Potentially life–threatening complications were reported with all techniques except for topical and intracameral local anaesthesias. Eight neurological complications were reported, seven of which occurred after peribulbar or retrobulbar anaesthesia.

The authors believe that the study demonstrates that newer techniques, such as sub–Tenon's, topical and topical–intracameral anaesthesia, offer a more favourable safety profile than more traditional methods.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.